Evidence map›Paper›PMID 40436992›Full record

ArticleScientific reports2025

Comparison of thrombectomy alone versus bridging thrombolysis in a US population using regression discontinuity analysis.

Youngran Kim, Sergio Salazar-Marioni, Rania Abdelkhaleq, Ananya Iyyangar, Diogo Haussen, Jonathan Grossberg, Jaydevsinh Dolia, Aqueel Pabaney, Mahmoud Mohammaden, Ameer Hassan and 26 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Youngran KimDepartment of Management, Policy, and Community Health, UTHealth School of Public Health, Houston, TX, USA.
Sergio Salazar-MarioniDepartment of Neurology, UTHealth McGovern Medical School, 6431 Fannin St, MSB 7.220, Houston, TX, 77030, USA.
Rania AbdelkhaleqDepartment of Neurology, UTHealth McGovern Medical School, 6431 Fannin St, MSB 7.220, Houston, TX, 77030, USA.
Ananya IyyangarDepartment of Neurology, UTHealth McGovern Medical School, 6431 Fannin St, MSB 7.220, Houston, TX, 77030, USA.
Diogo HaussenEmory School of Medicine/Grady Memorial Hospital, Atlanta, GA, USA.
Jonathan GrossbergEmory School of Medicine/Grady Memorial Hospital, Atlanta, GA, USA.
Jaydevsinh DoliaEmory School of Medicine/Grady Memorial Hospital, Atlanta, GA, USA.
Aqueel PabaneyEmory School of Medicine/Grady Memorial Hospital, Atlanta, GA, USA.
Mahmoud MohammadenEmory School of Medicine/Grady Memorial Hospital, Atlanta, GA, USA.
Ameer HassanDepartment of Neurology, University of Texas Rio Grande Valley, Valley Baptist Medical Center, Harlingen, TX, USA.
Wondwossen TekleDepartment of Neurology, University of Texas Rio Grande Valley, Valley Baptist Medical Center, Harlingen, TX, USA.
Hamzah SaeiDepartment of Neurology, University of Texas Rio Grande Valley, Valley Baptist Medical Center, Harlingen, TX, USA.
Mohamad AbdalkaderBoston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Piers KleinBoston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Taha NisarDepartment of Neurology, University of South Alabama, Mobile, AL, USA.
Adeel SaleemiDepartment of Neurology, University of South Alabama, Mobile, AL, USA.
Shahram MajidiDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Johanna FifiDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gabrielle ValestinDepartment of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Guillermo LinaresDepartment of Neurology, Saint Louis University, St. Louis, MO, USA.
Kara ChristopherDepartment of Neurology, Saint Louis University, St. Louis, MO, USA.
David S LiebeskindDepartment of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
Mouhammad JumaaProMedica Toledo Hospital, University of Toledo, Toledo, OH, USA.
Syed ZaidiProMedica Toledo Hospital, University of Toledo, Toledo, OH, USA.
Raul NogueiraDepartment of Neurology, University of Pittsburg, Pittsburg, PA, USA.
Brijesh MehtaMemorial Neuroscience Institute, Hollywood, FL, USA.
Joy SessaMemorial Neuroscience Institute, Hollywood, FL, USA.
Juan Vivanco-SuarezDepartment of Neurology, Neurosurgery and Radiology, University of Iowa, Iowa City, IA, USA.
Aaron Rodriguez-CalienesDepartment of Neurology, Neurosurgery and Radiology, University of Iowa, Iowa City, IA, USA.
Milagros Galecio-CastilloDepartment of Neurology, Neurosurgery and Radiology, University of Iowa, Iowa City, IA, USA.
Santiago Ortega-GutierrezDepartment of Neurology, Neurosurgery and Radiology, University of Iowa, Iowa City, IA, USA.
James SieglerCooper Medical School, Rowan University, Camden, NJ, USA.
Mary PenckoferCooper Medical School, Rowan University, Camden, NJ, USA.
Italo LinfanteMiami Cardiac and Vascular Institute, Miami, FL, USA.
Sunil A ShethDepartment of Neurology, UTHealth McGovern Medical School, 6431 Fannin St, MSB 7.220, Houston, TX, 77030, USA. ssheth@post.harvard.edu.
SVIN Registry Consortium

Funding

Deep Learning Enabled Endovascular Stroke Therapy Screening in Community HospitalsR01NS121154 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GIANCARDO, LUCA, SHETH, SUNIL · 2021 to 2025
$2.2M
NIH HHS R01NS121154NINDS NIH HHS R01 NS121154
6 · The paper itself

Abstract

The role of intravenous thrombolysis (IVT) in combination with endovascular thrombectomy (EVT) for the treatment of large vessel occlusion acute ischemic stroke has been evaluated exclusively outside the US, in randomized clinical trials which failed to demonstrate non-inferiority of skipping IVT. Because practice patterns and IVT dosing differ within the US, and prior observational US-based cohorts suggested improved clinical outcomes in patients who received IVT before EVT, a US-based evaluation is needed. This is a quasi-experimental study of a large US cohort using a regression discontinuity design (RDD) that enables the estimation of causal effects when randomization is not feasible. In this multi-center prospective cohort of patients undergoing EVT, we observed a sharp drop (65%) in the probability of receiving IVT at the cutoff of IVT eligibility time window while there were no significant differences in potential confounders including age, NIHSS, and ASPECTS at the cutoff. We found no association between IVT treatment and functional independence (mRS 0-2) at 90-days in patients undergoing EVT, nor in the secondary outcomes of excellent outcomes (mRS 0-1) at 90 days, mortality, symptomatic intracranial hemorrhage, first pass reperfusion, or final reperfusion.

Indexed as

Ischemic StrokeThrombectomyThrombolytic TherapyAgedAged, 80 and overEndovascular ProceduresFemaleFibrinolytic AgentsHumansMaleMiddle AgedNon-Randomized Controlled Trials as TopicProspective StudiesRegression AnalysisTreatment OutcomeUnited StatesFibrinolytic Agents

Identifiers

PMID40436992
PMCPMC12120054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.